INSUFICIENCIA CARDIACA

Received: 06/25/2016

Accepted: 08/15/2016

Insuf Card 2016; 11 (3): 115-121                

Pulmonary arterial hypertension in adult congenital heart disease

Impact and outcome Data from the GUTI-GUCH Registry

Claudio Gabriel Morós, Marisa Pacheco Otero, Gianina Faliva, María del Carmen Rubio,  Mariana López Daneri, Isabel Torres, Inés Abella, Álvaro Sosa Liprandi, Liliana Noemí  Nicolosi, María Grippo

Introduction

Adult congenital heart disease (ACHD) is one of the fastest-growing cardiology subgroups in recent years, due to early diagnosis and advances in surgical and endovascular treatment. It is estimated that 85-90% of patients with congenital heart disease survive until adulthood. The survival of these patients generates complications and sequelae that results in higher rates of hospitalizations and new surgeries, among other procedures.

It is estimated that 5 to 10% of patients with ACHD will develop pulmonary hypertension (PH) in its progression, which is currently the most frequent cause of arterial pulmonary hypertension (APH) after connective tissue diseases. Its appearance is related to a worse prognosis for the patient.

The objective of the present study was to analyze the epidemiological characteristics, clinical and pharmacological treatments in patients with APH and their impact on survival.